Medical treatment of diabetic retinopathy with somatostatin analogues

Related Experiment Videos

Stela S Palii1, Sergio Caballero, Gideon Shapiro

  • 1Pharmore, Inc., 5507 NW 80th Avenue, Gainesville, FL 32653, USA.

Expert Opinion on Investigational Drugs
|December 13, 2006
PubMed

Insights

Somatostatin analogues show promise in treating proliferative diabetic retinopathy by reducing retinal neovascularisation. These pharmacological treatments may offer a less invasive alternative to laser therapy for preventing vision loss.

Area of Science:

  • Ophthalmology
  • Endocrinology
  • Pharmacology

Background:

  • Proliferative diabetic retinopathy (PDR) is a leading cause of vision loss.
  • Current PDR management relies on laser photocoagulation, which can have adverse effects.
  • Pharmacological interventions are being explored to prevent or delay disease progression.

Purpose of the Study:

  • To review the mechanisms of retinal neovascularisation in PDR.
  • To evaluate the therapeutic potential of somatostatin analogues for PDR.
  • To discuss clinical trial results and propose treatment strategies.

Main Methods:

  • Literature review of neovascularisation mechanisms.
  • Analysis of somatostatin analogue pharmacology.
  • Summary of key clinical trials involving octreotide for PDR.

Main Results:

  • Somatostatin analogues demonstrate potential in reducing retinal vascular pathologies.
  • Octreotide clinical trials suggest efficacy in managing PDR.
  • Pharmacological regimens could complement or replace laser therapy.

Conclusions:

  • Somatostatin analogues represent a promising therapeutic avenue for PDR.
  • Further research and clinical application of these agents may reduce severe visual impairment.
  • Pharmacological treatments offer a potentially less invasive approach to PDR management.

Related Concept Videos

Diabetic Retinopathy01:27

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...